Research Papers:
Histopathological expression analysis of intercellular adhesion molecule 1 (ICAM-1) along development and progression of human melanoma
Metrics: PDF 1963 views | HTML 2586 views | ?
Abstract
Gilli Galore-Haskel1,*, Erez N. Baruch1,2,*, Amy L. Berg1, Iris Barshack3,4, Itzhak Zilinsky4,5, Camila Avivi3, Michal J. Besser1,2, Jacob Schachter1,4 and Gal Markel1,2,6
1Ella Lemelbaum Institute of Immuno-Oncology, Ramat-Gan, Israel
2Clinical Microbiology and Immunology, Tel-Aviv, Israel
3Institute of Pathology, Ramat-Gan, Israel
4School of Medicine, Sackler Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel
5Department of Plastic and Reconstructive Surgery, Ramat-Gan, Israel
6Talpiot Medical Leadership Program, Sheba Medical Center, Ramat-Gan, Israel
*These authors have contributed equally to this work
Correspondence to:
Gal Markel, email: [email protected]
Keywords: melanoma, ICAM-1, adhesion, progression
Received: April 12, 2017 Accepted: July 11, 2017 Published: September 14, 2017
ABSTRACT
Intercellular adhesion molecule 1 (ICAM-1) protein is an important adhesion molecule that facilitates metastasis on one hand, and on the other hand supports the immunological synapse necessary for T-cell mediated elimination. The expression pattern of ICAM-1 in melanoma was studied more than two decades ago, mainly in cell lines or in unmatched melanoma specimens. By using real time PCR we could not demonstrate a clear difference in ICAM-1 mRNA levels between primary melanocytes and primary cultures of metastatic melanoma. However, immunohistochemistry staining of progression tissue microarray comprised of samples of different disease stages derived from different patients, demonstrated a dramatic ICAM-1 upregulation particularly upon the transition from primary tumor to lymph node metastasis. There was no significant difference between lymph node and distant metastases. Importantly, these results were confirmed in an independent tissue microarray comprised of patient-paired specimens from progressive stages of the patient’s disease. These data indicate that ICAM-1 upregulation is required to initiate the lymphatic spread of melanoma (Stage III) but no further increase is associated with progression to remote organs (Stage IV).
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 20884